Ritter Pharmaceuticals Company

Ritter Pharmaceuticals discovers and commercializes treatments for gastrointestinal diseases.
Ritter Pharmaceuticals, Inc. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal and metabolic diseases. We are discovering a new frontier in human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into safe and effective applications that can have a meaningful impact on a patient’s health.
Our pipeline of novel microbiome modulators selectively increase the growth of beneficial bacteria in the colonic ecosystem and create a meaningful impact on a patient’s health. Our first therapy, RP-G28, is currently under development for the treatment of lactose intolerance and has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide. RP-G28 has been studied in a Phase 2 clinical trial and is a first-in-class compound.
Technology: Personalized Medicine
Industry: Precision Medicine
Headquarters: Los Angeles
Founded Date: 2004
Employees Number: 11-50
Funding Status: IPO

Visit Website
Register and Claim Ownership